间充质干细胞及其外泌体治疗器官纤维化的研究进展  

Research Progress of Mesenchymal Stem Cells and Their Exosomes in the Treatment of Organ Fibrosis

作　　者：熊宇 刘红梅 李贤哲 王硕 韩露 何黎黎 袁志翔 XIONG Yu;LIU Hongmei;LI Xianzhe;WANG Shuo;HAN Lu;HE Lii;YUAN Zhixiang(School of Pharmacy,Southwest Minzu University,Chengdu 610041,China)

机构地区：[1]西南民族大学药学院,四川成都610041

出　　处：《药学进展》2024年第6期471-480,I0003-I0006,共14页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.81973265);中央高校基本科研基金(No.2021107);四川省中央引导地方科技发展专项(No.2021ZYD0070);四川省中医药管理局科学技术研究专项(No.2020LC0199)。

摘　　要：器官纤维化以细胞外基质(ECM)过度沉积为特征,是慢性脏器疾病发展为癌症的中间病理过程。目前尚无有效的抗纤维化方法。间充质干细胞(MSCs)作为多能干细胞,不仅可通过增殖分化、免疫调节、旁分泌以及归巢作用,促进组织纤维化的修复,而且其分泌的外泌体亦可通过将其活性成分转移到损伤细胞,或作为递送载体靶向作用于受体细胞,为治疗器官纤维化疾病提供了新的选择。针对肺、肝、肾、心脏、皮肤以及胰腺纤维化,综述MSCs及其外泌体在治疗器官纤维化疾病中的机制和应用,为后期发展纤维化的干细胞疗法提供参考。Organ fibrosis is characterized by excessive deposition of extracellular matrix(ECMs),and is an intermediate pathological process of chronic organ disease developing into cancer.At present,there is still no effective anti-fibrosis strategy.As pluripotent stem cells,mesenchymal stem cells(MSCs)can promote the repair of fibrotic tissues by differentiation,immune regulation,paracrine and homing;besides,their exosomes(MSC-Exos)as the delivery vectors show great potential in the treatment of organ fibrosis by transferring their active components to injured cells or targeting recipient cells,providing a new option for the treatment of organ fibrosis.Based on liver fibrosis,lung fibrosis,kidney fibrosis,cardiac fibrosis,skin fibrosis and pancreatic fibrosis,this paper summarizes the mechanisms and applications of MSCs and MSC-Exos in the treatment of organ fibrosis,in the hope of providing new insights to further develop stem-cell therapyforfibrosis.

关 键 词：间充质干细胞 外泌体 器官纤维化 靶向治疗 药物递送 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]